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Background: In patients with type 2 diabetes, chronic kidney disease (CKD) is associated with increased risk of
hypoglycaemia and death. Yet, it remains uncertain whether hypoglycaemia-associated mortality is modified by CKD.
Methods: Type 2 diabetic patients, with or without CKD at enrolment were observed between 1995 and 2007, and
followed up till 2009 at hospital medical clinics. We used additive interaction, estimated by relative excess risk due to
interaction (RERI) and attributable proportion due to interaction (AP) to examine possible synergistic effects between
CKD and severe hypoglycaemia (defined as hospitalisations due to hypoglycaemia in the 12 months prior to enrolment)
on the risk of death.
Results: In this cohort of 8,767 type 2 diabetic patients [median age: 58 (interquartile range: 48 to 68) years; disease
duration: 5 (1 to 11) years, men: 47.0%], 1,070 (12.2%) had died during a median follow-up period of 6.66 years
(3.42-10.36) with 60,379 person-years.Upon enrolment, 209 patients had severe hypoglycaemia and 194 developed
severe hypoglycaemia during follow-up (15 patients had both). In multivariable analysis and using patients without severe
hypoglycaemia nor CKD as the referent group (683 deaths in 7,598 patients), severe hypoglycaemia alone (61 deaths in
272 patients) or CKD alone (267 death in 781 patients) were associated with increased risk of death [Hazard ratio, HR:
1.81(95%CI: 1.38 to 2.37) and 1.63 (1.38 to 1.93) respectively]. Having both risk factors (59 deaths in 116 patients) greatly
enhanced the HR of death to 3.91 (2.93 to 5.21) with significant interaction (RERI: 1.46 and AP: 0.37, both p-values < 0.05).
Conclusions: Severe hypoglycaemia and CKD interact to increase risk of death in type 2 diabetes patients.Background
When glycaemic control is targeted to a glycated haemo-
globin (HbA1c) of 7% in patients suffering from type 2
diabetes, microvascular and macrovascular complica-
tions and all-cause mortality is reduced [1]. Large scale
randomized controlled trials including the ADVANCE
(Action in Diabetes and Vascular disease: preterAx and
diamicroN modified release Controlled Evaluation) [2],
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) [3] and VADT (Veteran Affairs Diabetes Trial)
[4] have been conducted to determine whether intensive* Correspondence: jchan@cuhk.edu.hk
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unless otherwise stated.lowering of HbA1c to less than 7% would further improve
cardiovascular outcomes [2-4]. However, the results from
the ACCORD study rekindled the debate on risk-benefit
ratio of these intensive strategies with the premature
discontinuation of the intensive blood-glucose lowering
arm in the ACCORD Study [3,5,6]. Subsequent analysis of
both the ACCORD and ADVANCE Study revealed that
while intensive glycaemic control increased the risk of
severe hypoglycaemia which was associated with in-
creased risk of death, the hazard ratios (HR) were in fact
lower in the intensively-treated group, suggesting that
intensive monitoring with prompt corrective actions
might mitigate the potential harm of intensive blood
glucose lowering [6,7].
However, due to volunteer effects and to the unique
environment of a randomized controlled trial setting,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remains uncertain. To date, there is a paucity of long-
term data with adequate documentation of confounders
to allow detailed analysis of the causes and consequences
of hypoglycaemia in type 2 diabetes [8]. To this end,
renal dysfunction is a potential risk amplifier for death
associated with hypoglycaemia. Microalbuminuria is
known to be the earliest clinical evidence of diabetic ne-
phropathy and up to 20-40% of diabetic patients pro-
gress to overt nephropathy if left untreated [9]. In Asia,
micro- and macroalbuminuria are common in type 2
diabetic patients, affecting 50-60% of patients with type
2 diabetes [10] while about 16% of type 2 diabetic pa-
tients suffer from chronic kidney disease (CKD) [11].
Given the high rates of diabetic nephropathy (usually
considered as nephropathy with or without CKD) and
CKD (based on eGFR alone) in Asian populations and
the high risk of hypoglycaemia and clinical outcomes in
CKD patients, we questioned whether the co-occurrence
of these conditions will further increase the risk of
future events. In a prospective registry with detailed
documentation of risk factors, complications, drug use
and clinical outcomes, we explored the prognostic sig-
nificance of CKD on incident severe hypoglycaemia and
the interactive effects of prevalent CKD and severe
hypoglycaemia on future risk of clinical outcomes.
Methods
We retrospectively analysed the data of a prospective
observational study of type 2 diabetic patients enrolled
into the Hong Kong Diabetes Registry. Upon enrolment,
diabetic patients undergo comprehensive assessments
which follow a structured protocol whose methodology
has been described previously [11-14]. Briefly, the Hong
Kong Diabetes Registry was established in 1995 at the
Prince of Wales Hospital, which serves a population of
over 1.2 million. Since 1995, diabetic patients attending
medical clinics at the Prince of Wales Hospital can be
referred to the Diabetes Centre for comprehensive as-
sessment based on the European DIABCARE protocol
[15]. Hong Kong has a heavily subsidized healthcare sys-
tem, so the vast majority of patients with chronic ill-
nesses, including diabetes, are managed in public
hospitals governed by the Hospital Authority (HA),
which provide for 95% of the total hospital bed-days in
Hong Kong [12]. Once the participants are entered into
the Registry, their outcomes including hospital admis-
sions will be monitored until the death of the patient
[11-14]. From 1995 to the 31st December 2007, 10,129
patients have been enrolled into the cohort. After ex-
cluding 417 patients with type 1 diabetes (including
missing data on classification of diabetes type), and 945
with missing variables used in the analysis, 8,767 pa-
tients were included in this analysis.The enrolled patients periodically underwent a com-
prehensive 4-hour assessment for quality assurance in-
cluding interview by diabetes nurses, anthropometric
measurements, blood and urine tests, fundus examin-
ation and podiatry assessment. After 8 hours of over-
night fast, blood was sampled for assay of fasting plasma
lipids [total cholesterol (TC), HDL-C, triglyceride (TG)
and calculated LDL-C], glucose, HbA1c, renal and liver
function tests. We used spot urinary albumin: creatinine
ratio (ACR) to define albuminuria (ACR ≥ 2.5 mg/mmol
in men and ≥3.5 mg/mmol in women). The abbreviated
Modification of Diet in Renal Disease Study (MDRD)
formula recalibrated for Chinese [16] was used to define
CKD as eGFR < 60 ml/min/1.73 m2 [17]. All laboratory
analyses were performed using standard methods in the
Department of Chemical Pathology of the Prince of Wales
Hospital. The laboratory is accredited by the Australian
National Association of Testing Authorities. Informed
written consent was obtained from all participants and the
study was approved by the Chinese University of Hong
Kong Clinical Research Ethics Committee prior to its
initiation.
Severe hypoglycaemia was defined as one or more hos-
pitalisations due to hypoglycaemia 12 months prior to
enrolment (‘at enrollment’), in order not to miss events
and subjects with characteristics relevant to this present
analysis, or during the follow-up period [14], as defined
from enrolment to death or 31st January, 2009. Using
the same definintion for severe hypoglycaemia, we had
previously reported that severe hypoglycaemia identified
vulnerable type 2 diabetic patients who were at risk for
premature death and were associated with cancer sub-
phenotypes [14]. We ascertained all clinical outcomes
using the HA Central Computer Management System
(CMS), which records diagnoses of all hospital dis-
charges, including mortality based on the International
Classification of Diseases, Ninth Revision (ICD-9). The
mortality data was cross-checked with the Hong Kong
Death Registry and the cause of death was defined by
the principal discharge diagnosis.
Statistical analysis
The Statistical Analysis System (Release 9.30) was used
to perform all analyses (SAS Institute Inc., Cary, NC,
USA) unless specified. Follow-up time was calculated as
the period in years from the first enrolment to the date
of death or 31st January 2009, whichever came first. All
data were expressed as mean ± SD or median (interquar-
tile range, IQR). Cox proportional hazard regression was
used to obtain hazard ratio (HR) and 95% confidence
interval (CI) of variables of interest. We used the Yes/
No coding scheme for all major drug use at enrolment.
Immortal time is defined as the period of time without
exposure to hypoglycemia from the point of enrolment
Kong et al. BMC Endocrine Disorders 2014, 14:48 Page 3 of 10
http://www.biomedcentral.com/1472-6823/14/48into the study to the date of first hospitalization due to
hypoglycemia during the follow-up period in this study.
This however, may introduce immortal time bias [18,19].
In this regard, we performed a validation study of vari-
ous methods to cope with immortal time bias and found
that removal of immortal time led to the least inflated
hazard ratio [20]. Thus, in this study, we excluded 896.8
person-years of immortal time from the analysis by mov-
ing the commencement point of follow-up from date of
enrolment to the time of first hospitalization due to
hypoglycemia during follow-up. For patients with severe
hypoglycemia at enrolment, the immortal period was
considered ‘0’ and their clinical profile at enrolment was
used for analysis. For patients who developed severe
hypoglycemia during follow-up, the enrolment was moved
to the time of severe hypoglycemia during follow-up. As
the metabolic profile may deteriorate over time, as in our
validation study [20], we used multivariable linear regres-
sion to obtain partial regression coefficients of age (βa) and
duration of diabetes (βb) from all other covariables at enrol-
ment and used the estimated values of HbA1c, body mass
index (BMI), systolic blood pressure (SBP), diastolic blood
pressure (DBP), LDL-C, HDL-C, TG, ACR, and eGFR de-
rived from the following formulae: Xt = Xb + βa Ti + βb Ti,
where Xt is the value at hypoglycemia during follow-up,
Xb is the value at baseline, and Ti is the immortal time
(Additional file 1: Table S1 for βa and βb). Prior cardiovas-
cular diseases (CVD) and cancer were re-estimated taking
into consideration whether these events occurred at enrol-
ment, or during the immortal time period.
We further used relative excess risk due to interaction
(RERI) and attributable proportion due to interaction
(AP) [18,21] to estimate additive interaction between hypo-
glycemia and CKD on all-cause death. The RERI is the ex-
cess risk due to interaction relative to the risk without
exposure. AP refers to the attributable proportion of disease
due to interaction in persons with both exposures. RERI >0
or AP > 0 indicates significant additive interaction.
A three-step adjustment scheme was used to control for
covariables. First, we obtained the HR in univariable ana-
lysis, followed by further adjustment for age, sex, use of
tobacco and alcohol, BMI, duration of diabetes, HbA1c,
systolic BP, LDL-C, HDL-C, TG, natural log-transformed
(spot urinary ACR + 1), eGFR, prior CVD and/or cancer
at enrolment and drug use at baseline.
The plots of LOG [−LOG (Survival function)] versus
LOG (follow-up time in years) were used to check pro-
portional hazards assumption for categorical variables,
while the Supremum test was used to check the assump-
tion for continuous variables [19]. In case of violation of
the proportional hazard assumption, a stratified Cox model
analysis on the variable concerned was used to adjust for
its confounding effect. To avoid co-linearity, SBP but not
DBP, and BMI but not waist circumference, were used inthe model fitting. Pearson correlation was used to exclude
highly correlated variables from the models (correlation co-
efficient > 0.60) [22]. A p value <0.05 (two-sided) was con-
sidered statistically significant.
The Statistical Package for Social Sciences version 16
(SPSS, Chicago, US) was used to obtain the adjusted plot
of cumulative mortality stratified by hypoglycemia and
CKD and their combination over time.
Results
The median age of the cohort was 58 years (IQR:48–68)
with a disease duration of 5 [1-11] years. During a me-
dian follow-up period of 6.66 (3.42-10.36) years with
60,379 person-years, 1,070 patients had died with a mor-
tality rate of 17.7 (16.7-18.8) per 1000-person-years. The
deceased were older, more likely to be men, ex/current
smokers and alcohol drinkers, had longer disease dur-
ation, higher SBP, HbA1c, LDL-C and lower BMI and
HDL-C than those who survived. They were also more
likely to have history of CVD and cancers (all p < 0.05),
poorer renal function (higher ACR, lower eGFR) and
more frequent severe hypoglycaemia events (both at en-
rolment and during follow-up) (p < 0.0001) (Table 1).
After excluding 209 patients who had documented
hypoglycemia upon enrollment, 179 patients developed
hypoglycemia with an event rate of 3.02(95%CI: 2.57-
3.46) per 1,000 person-years. In this cohort, 897 patients
(10.2%) had CKD at enrollment, amongst whom, 116
(12.9%) had hospitalizations due to hypoglycemia (50 at
enrollment, 60 during follow-up and 6 had events both
at enrollment and during follow-up). In patients without
CKD (n = 7870), 272(3.46%) had hospitalizations due to
hypoglycemia (144 at enrollment, 119 during follow-up
and 9 with events both at enrollment and during follow
up) with higher rate of hypoglycemia in patients with
CKD than those without (p < 0.0001).
In multivariable analysis, severe hypoglycemia predicted
mortality among patients with CKD with a HR of 2.63
(1.95 to 3.55) and to a lesser extent, among those without
CKD [1.72(1.31 to 2.26)] (Table 2). After adjusting for con-
founders, CKD enhanced the HR of severe hypoglycemia
for all-cause mortality from 1.81(1.38 to 2.37) to 3.91
(2.93 to 5.21) (Table 3) with significant additive inter-
action between hypoglycemia and CKD (RERI: 1.46
(0.31 to 2.61, p = 0.0126); AP: 0.37(0.17 to 0.58, p = 0.0177)
(Additional file 2: Table S2). From 1 December 1996 to 30
July 2005, 52.7% (n = 4618) of the diabetic patients have
documented use of sulfonylurea and after further ad-
justment for the use of sulfonylurea during this period,
this had little impact on the HRs.
Figure 1 shows the multivariable cumulative mortality
of patients categorized by hypoglycemia and CKD with
the highest mortality rate in those with both CKD and
hypoglycemia.
Table 1 Clinical and biochemical characteristics of the study cohort
Patients who survived (n = 7697) Patients who died (n = 1070)
Median (25th to 75th) or n(%) Median (25th to 75th) or n(%) P value†
Age, years 57(47–66) 69(62–75) <0.0001
Male gender 3586(46.6%) 533(49.8%) 0.0477
Smoking status <0.0001
Ex-smoker 1094(14.2%) 256(23.9%)
Current smoker 1310(17.0%) 197(18.4%)
Alcohol intake <0.0001
Ex-drinker 846(11.0%) 206(19.3%)
Current drinker 720(9.4%) 57(19.3%)
Body mass index, kg/m2 24.9(22.6-27.6) 24.2(21.8-26.6) <0.0001
Duration of diabetes, years 5(1-10) 9(4–15) <0.0001
Systolic BP, mmHg 132(120–145) 144(128–159) <0.0001
Diastolic BP, mmHg 75(68–82) 75(68–83) 0.4583
HbA1c, % 7.2(6.3-8.4) 7.5(6.5-8.9) <0.0001
LDL-C, mmol/L 2.98(2.40-3.60) 3.14(2.50-3.90) <0.0001
HDL-C, mmol/L 1.28(1.09-1.52) 1.25(1.03-1.54) 0.0108
Triglyceride, mmol/L 1.37(0.97-1.99) 1.36(0.98-2.00) 0.6668
Spot urinary ACR, mg/mmol 1.69(2.72) 13.42(2.06-120.20) <0.0001
Prior cardiovascular disease 972(12.6%) 321(30.0%) <0.0001
Prior cancer 193(2.9%) 69(6.5%) <0.0001
Medication use at enrollment
Renin-angiotensin system inhibitors 1687(21.9%) 306(28.6%) <0.0001
Lipid lowering drugs 1509(19.6%) 170(15.9%) 0.0038
Oral anti-diabetes drugs 5335(69.3%) 626(58.5%) <0.0001
Insulin 1197(15.6%) 311(29.1%) <0.0001
CKD events at baseline
eGFR, ml min−1 1.73 m−2 at baseline 105.6(86.2-126.0) 79.0(51.7-104.7) <0.0001
eGFR < 60 ml min−1 1.73 m−2 at baseline 571(7.4%) 326(30.5%) <0.0001
Major hyopglycaemia events
12 months prior to enrollment 146(1.9%) 63(5.9%) <0.0001
During follow-up only§ 122(1.6%) 57(5.3%) <0.0001
Either of them 268(3.5%) 120(11.2%) <0.001
Abbreviations: HbA1c, glycated haemglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; ACR,
albumin:creatinine ratio; eGFR, estimated glomerular filtration rate;
†, Derived from Wilcoxon Two-Sample test or Chi-squared test where appropriate;
§, Defined as hypoglycaemia events that required hospitalisations. For patients who developed the event during follow-up, the time period from enrollment to
the time of hospitalisation was removed as the immortal time period so that the follow-up started at the time of admission for hypoglycaemia. In these patients,
all baseline values of continuous covariables and prior cancer and cardiovascular disease were re-estimated by treating the time of admission for hypoglycaemia
as the enrollment date.
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(23.4%, n = 250), CVD (22.9%, n = 245), respiratory dis-
ease (15.1%, n = 162) and renal disease (13.6%, n = 146).
After adjustment for confounders, CKD was an inde-
pendent predictor for cardiovascular [1.54 (1.20 to 2.13)]
related deaths, whereas severe hypoglycaemia was an in-
dependent predictor for renal [3.10 (1.97 to 4.89)] and
cancer-related deaths [1.97 (1.26 to 3.07)] (Table 4).Discussion
To our knowledge, this study is the first report on the
increased risk of all-cause mortality in Chinese type 2
diabetic patients with co-occurrence of hypoglycaemia
episodes and CKD in a real-world setting. Compared to
patients without CKD or severe hypoglycaemia, the co-
occurrence of these two risk factors markedly increased
the risk of all-cause mortality by four-fold. While CKD
Table 2 Hazard ratios of severe hypoglycaemia and chronic kidney disease (CKD) for the risk of all-cause death in
patients with type 2 diabetes
Exposures Number of death (%) Hazard ratio 95% CI P value
Independent Models
Patients without CKD
Model 1: Hypoglycemia 749(9.45%) 3.48 2.68 to 4.52 <0.0001
Model 2: Hypoglycemia 749(9.45%) 1.81 1.38 to 2.38 <0.0001
Model 3: Hypoglycemia 749(9.45%) 1.72 1.31 to 2.26 <0.0001
Patients with CKD
Model 1: Hypoglycemia 326(36.34%) 2.87 2.16 to 3.82 <0.0001
Model 2: Hypoglycemia 326(36.34%) 2.70 2.00 to 3.64 <0.0001
Model 3: Hypoglycemia 326(36.34%) 2.63 1.95 to 3.55 <0.0001
Interactive Models
Model 1
Hypoglycemia = Yes and CKD = No 61(22.43%) 3.47 2.67 to 4.52 <0.0001
Hypoglycemia = No and CKD = Yes 267(34.19%) 5.70 4.93 to 6.57 <0.0001
Hypoglycemia = Yes and CKD = Yes 59(50.86%) 16.21 12.38 to 21.23 <0.0001
Hypoglycemia = No and CKD = No 683(8.99%) Reference
Model 2
Hypoglycemia = Yes and CKD = No 61(22.43%) 1.87 1.43 to 2.44 <0.0001
Hypoglycemia = No and CKD = Yes 267(34.19%) 1.75 1.49 to 2.07 <0.0001
Hypoglycemia = Yes and CKD = Yes 59(50.86%) 4.32 3.25 to 5.75 <0.0001
Hypoglycemia = No and CKD = No 683(8.99%) Reference
Model 3
Hypoglycemia = Yes and CKD = No 61(22.43%) 1.81 1.38 to 2.37 <0.0001
Hypoglycemia = No and CKD = Yes 267(34.19%) 1.63 1.38 to 1.93 <0.0001
Hypoglycemia = Yes and CKD = Yes 59(50.86%) 3.91 2.93 to 5.21 <0.0001
Hypoglycemia = No and CKD = No 683(8.99%) Reference
Model 1, not adjusted for other covariables at enrollment;
Model 2, adjusted for age, sex, body mass index (BMI), smoking status, alcohol use, low-density lipoprotein cholesterol (LDL-C), high density-lipoprotein choles-
terol, triglyceride, systolic blood pressure (SBP), HBA1c, duration of disease, and Ln (urinary albumin to creatinine ratio [ACR] +1), prior cardiovascular disease and
prior cancer. As BMI violated the proportional hazard assumption, Cox models stratified on quartiles of BMI were used to adjust for the confounding effect of BMI;
Model 3, further adjusted for drug use at enrollment, including lipid lowering drugs, renin-angiotensin system inhibitors, oral anti-diabetes drugs and insulin.
Table 3 Further adjustment for the use of sulfonylurea from 1 December 1996 to 30 July 2005 in model 3 of Tables 2,
3
Exposures Number of death (%) Hazard ratio 95% CI P value
Independent Models
Patients without CKD
Hypoglycemia 749(9.45%) 1.72 1.31 to 2.26 <0.0001
Patients with CKD
Hypoglycemia 326(36.34%) 2.64 1.96 to 3.56 <0.0001
Interactive Models
Hypoglycemia = Yes and CKD = No 61(22.43%) 1.81 1.38 to 2.37 <0.0001
Hypoglycemia = No and CKD = Yes 267(34.19%) 1.63 1.38 to 1.93 <0.0001
Hypoglycemia = Yes and CKD = Yes 59(50.86%) 3.91 2.93 to 5.21 <0.0001
Hypoglycemia = No and CKD = No 683(8.99%) Reference
Covariables adjusted were listed in model 3 of Table 2 and ever use of sulfonylurea from 1 December 1996 to 30 July 2005.
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Hypoglycemia=Yes & CKD=Yes (top)
Hypoglycemia=Yes & CKD=No (mid-top)
Hypoglycemia=No & CKD=Yes(mid-bottom)
Hypoglycemia=No & CKD=No(bottom)
Figure 1 Cumulative incidence of all-cause death stratified by the presence of chronic kidney disease (CKD) and severe hypoglycaemia.
Legend: The model adjusted for age, sex, body mass index (BMI), smoking status, alcohol use , low-density lipoprotein cholesterol (LDL-C), high
density-lipoprotein cholesterol (HDL-C), triglyceride (TG), systolic blood pressure (SBP), HBA1c, duration of disease, and log (urinary albumin to
creatinine ratio [ACR] +1), prior history of cardiovascular disease and cancer as well as drug use at enrollment, including lipid lowering drugs,
renin-angiotensin system inhibitors, oral anti-diabetic drugs and insulin; P < 0.0001.
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renal and cancer-related deaths.
The premature termination of ACCORD study has led
to heated debates regarding the safety of tight glycaemic
control and the impact of hypoglycaemia on mortality
[5,6]. In the ACCORD Study, the all-cause mortality rate
(mainly due to CVD) was 21% higher in the intensive
treatment group (target HbA1c < 6%) compared to the
standard treatment group (target HbA1c 7-7.9%) [3].
Although detailed post-hoc analysis did not reveal direct
association between hypoglycaemia and CVD [6], these
findings have alerted clinicians to the importance of in-
dividualizing treatment goals and strategiesin order to
maximize benefits and minimize harm [23].
Hitherto, the risk-benefit ratios of intensive glycaemic
control in type 2 diabetes have not been sufficiently studied
[8]. While intensive glycaemic control may help to reduce
the risks of development of diabetes-related complications,
tight control of glycaemia inevitably leads to hypoglycaemia.
In diabetic patients with advanced diseases, hypoglycaemia
may amplify the adverse consequences of cognitive impair-
ment, dementia, cardiac ischemia and arrhythmia [24,25]. In
the United Kingdom Prospective Diabetes Study (UKPDS),
the annual rate of major hypoglycaemia, defined by symp-
toms requiring assistance from a third-party or medical
intervention, ranged from 0.7% in patients treated with oral
drugs to 1.8% in the insulin-treated patients [26]. In the AD-
VANCE Study, during a median follow-up period of 4 years,
231 (2.1%) patients developed severe hypoglycaemia(defined as blood glucose < 2.8 mmol/l with neurological
dysfunction and third-party assistance) which was associ-
ated with 2–3 fold increased risk of microvascular compli-
cations, cardiovascular events and all-causes mortality [7].
Additive effects between CKD and hypoglycaemia on death
Our results, collected in a usual care setting, indicated that
severe hypoglycaemia occurred in 4.4% of patients with
type 2 diabetes with an annualized event rate of approxi-
mately 0.3%. After adjusting for covariables, hypoglycaemia
markedly increased the risk of all-cause mortality, espe-
cially in those with CKD, which accounted for 10.2% of the
cohort. Besides malnutrition and reduced gluconeogenesis
(approximately one fifth of plasma glucose originated from
renal gluconeogenesis), diabetic patients with CKD often
have altered drug metabolism and autonomic neuropathy
with hypoglycaemic unawareness, which put them at high
risk of hypoglycaemia [27]. In this context, renal dysfunc-
tion is a major risk factor for drug-induced hypoglycaemia
[28]. In a 15-month retrospective study reported by our
group [29], among 127 type 1 and type 2 diabetic pa-
tients hospitalized due to drug-induced hypoglycaemia
(which accounted for 0.5% of the total medical admis-
sions), factors includingold age, institutionalization and
renal dysfunction predicted hypoglycaemia-associated
death. Many of these hypoglycaemia events were related
to the use of sulphonylureas. Other researchers have re-
ported experimental and clinical data showing that
hypoglycaemia might cause arrhythmia, abnormal
Table 4 Hazard ratios of severe hypoglycaemia events and chronic kidney disease (CKD) for the risk of cause-specific
death in patients with type 2 diabetes
Causes of death Number of death (%) Hazard ratio 95% CI P value
Cardiovascular disease
Model 1
Hypoglycemia events 14(3.61%) 1.48 0.86 to 2.54 0.1619
CKD 83(9.25%) 7.15 5.45 to 9.38 <0.0001
Model 2
Hypoglycemia events 0.99 0.57 to 1.71 0.9603
CKD 1.63 1.19 to 2.23 0.0021
Model 3
Hypoglycemia events 0.99 0.57 to 1.72 0.9790
CKD 1.54 1.20 to 2.13 0.0081
Renal disease
Model 1
Hypoglycemia events 26(6.70%) 4.27 2.76 to 6.61 <0.0001
CKD 88(9.81%) 20.92 14.79 to 29.58 <0.0001
Model 2
Hypoglycemia events 3.20 2.03 to 5.02 <0.0001
CKD 3.47 2.35 to 5.15 <0.0001
Model 3
Hypoglycemia events 3.10 1.97 to 4.89 <0.0001
CKD 3.42 2.29 to 5.11 <0.0001
Respiratory disease
Model 1
Hypoglycemia events 13(3.35%) 2.29 1.29 to 4.07 0.0048
CKD 45(5.02%) 5.19 3.65 to 7.39 <0.0001
Model 2
Hypoglycemia events 1.24 0.69 to 2.23 0.4741
CKD 1.54 1.03 to 2.31 0.0358
Model 3
Hypoglycemia events 1.21 0.67 to 2.18 0.5235
CKD 1.44 0.95 to 2.17 0.0845
All-site cancer
Model 1:
Hypoglycemia events 24(6.19%) 3.21 2.10 to 4.92 <0.0001
CKD 28(3.12%) 1.39 0.94 to 2.08 0.1030
Model 2
Hypoglycemia events 2.09 1.34 to 3.26 0.0011
CKD 1.00 0.64 to 1.54 0.9805
Model 3
Hypoglycemia events 1.97 1.26 to 3.07 0.0027
CKD 0.92 0.59 to 1.44 0.7192
Adjustment schemes for models 1 to 3 were the same as listed in Tables 2 and 3.
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substantially increase the risk of CVD [24].
Apart from common risk factors shared by CKD and
CVD, changes in micro-environment associated with
CKD can amplify CVD risk [30]. In a meta-analysis of
105,872 participants, from general population cohorts,
both eGFR and albuminuria were independent predictors
for all-cause and cardiovascular mortality [31]. The high
CVD risk associated with CKD is multifactorial including
anaemia, abnormal bone metabolism, vascular calcifi-
cation, low grade inflammation and oxidative stress [32].
Using this Registry, we have reported the predictive values
of reduced eGFR for micro- and macrovascular complica-
tions [11] as well as all-cause mortality [33]. These observa-
tional findings concur with the VADT Study, showing that
renal dysfunction and macroalbuminuria also predict cor-
onary heart diseases [4].
Hypoglycaemia and all-cause deaths
In our analysis, type 2 diabetic patients who died before
the censor date were more likely to use insulin and renin-
angiotensin system (RAS) inhibitors. This pattern of drug
usage was compatible with long disease duration, progres-
sive beta cell failure and high cardiovascular-renal risk in
these subjects. Since many patients were enrolled in the
1990’s when the beneficial effects resulted from the utility
of these drugs was less well documented, the usage of RAS
inhibitors and statin was relatively low which might have
contributed to the high event rates in this cohort. In our
previous analysis [12], we reported that urinary ACR, eGFR
and insulin use predicted all-cause death. The combination
of renal dysfunction and insulin use put patients at high
risk for hypoglycaemia if they were not monitored closely.
Of note, over 20% of our patients died of cancer, a propor-
tion similar to CVD-related deaths. Thus, multiple organ
dysfunction, abnormal metabolic milieu and malnutrition,
often associated with CKD and cancer [34,35], might con-
tribute to the additive interactions between CKD and
hypoglycaemia on all-cause death in our cohort. In support
of these findings, we also found that while CKD predicted
CVD-related deaths, hypoglycaemia predicted cancer and
renal-related deaths. Thus, despite the theoretical risk of
hypoglycaemia for CVD, our study was only able to con-
firm the risk association of hypoglycaemia with all-cause
but not CVD-related deaths, which is in agreement with
the ACCORD study. Taken together, we argue that
hypoglycaemia might be a marker of frailty and multiple
organ dysfunction including cancer which should alert cli-
nicians to reassess the clinical status and screen for silent
conditions such as CKD and occult cancer. To this end,
the 1.3-3 fold increased risk for multiple morbidities in-
cluding cancer in diabetes is now well recognized [36,37]
and support the frequent co-occurrence of hypoglycaemia,
CKD and non-CVD deaths in our analysis.Limitations
Firstly, in this real-world dataset, all clinical outcomes
were ascertained by ICD-9 codes, which might contain er-
rors due to misclassification and/or under-coding. How-
ever, validation analysis suggested that the estimated
predictive value of administrative data for clinical out-
comes could be as high as 95% for acute myocardial in-
farction and stroke [38,39]. Secondly, we only included
severe hypoglycaemic episodes requiring hospitalizations,
which were specific but not sensitive indicators of these
adverse events. Since our database did not systematically
capture minor hypoglycaemia not requiring admission,
under-estimation of true rates of hypoglycaemia was likely.
Although our analysis did not confirm the risk association
between severe hypoglycaemia and CVD-related deaths, it
remained plausible that multiple minor hypoglycaemic ep-
isodes could have cumulative adverse effects on cardiovas-
cular and cerebrovascular functions with direct or indirect
impacts on mortality. Thirdly, we captured and adjusted
the drug use at baseline but did not have data on changes
of concomitant medications and metabolic profiles during
the whole follow-up. Fourthly, only eGFR at baseline was
used to estimate the occurrence of CKD events because
we did not measure eGFR on a regular basis among all the
patients in our cohort. Thus, some CKD events during
follow-up had been missed.
Conclusions
Using a real-world registry, we confirmed the inde-
pendent and interactive effects of CKD and severe
hypoglycaemia on all-cause death, with hypoglycaemia
independently predicting cancer and renal-related death.
These findings added to the growing body of literature
on the vulnerability of diabetic patients with CKD and
called for comprehensive assessment in patients with
hypoglycaemia to screen for silent conditions such as
CKD and cancer as well as review of treatment regimens
to reduce the risk of hypoglycaemia in patients with
these comorbidities.
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